Preclinical studies indicate that targeting polo-like kinase 1 (PLK-1) with selective inhibitors like BI-2536, alone or combined with MDM2 inhibition, effectively reduces cell viability, restores p53 function, and induces apoptosis in adrenocortical carcinoma (ACC) cells, suggesting a promising therapeutic approach for ACC (58, 59). Here, MDM2 is linked to adrenal cortex carcinoma.